These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 11685733)

  • 1. Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer.
    Small EJ; Bok R; Reese DM; Sudilovsky D; Frohlich M
    Semin Oncol; 2001 Aug; 28(4 Suppl 15):71-6. PubMed ID: 11685733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
    Sinibaldi VJ; Carducci MA; Moore-Cooper S; Laufer M; Zahurak M; Eisenberger MA
    Cancer; 2002 Mar; 94(5):1457-65. PubMed ID: 11920502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer.
    Sitka Copur M; Ledakis P; Lynch J; Hauke R; Tarantolo S; Bolton M; Norvell M; Muhvic J; Hake L; Wendt J
    Semin Oncol; 2001 Aug; 28(4 Suppl 15):16-21. PubMed ID: 11685724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.
    Picus J; Halabi S; Kelly WK; Vogelzang NJ; Whang YE; Kaplan EB; Stadler WM; Small EJ;
    Cancer; 2011 Feb; 117(3):526-33. PubMed ID: 20862750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
    Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
    Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer.
    Taplin ME; Bubley GJ; Rajeshkumar B; Shuster T; Ko YJ; Morganstern DE
    Semin Oncol; 2001 Aug; 28(4 Suppl 15):32-9. PubMed ID: 11685726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer.
    Vaishampayan U; Fontana J; Du W; Hussain M
    Urology; 2002 Dec; 60(6):1050-4. PubMed ID: 12475668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer.
    Mathew P; Logothetis CJ; Dieringer PY; Chen I; Pagliaro LC; Bekele BN; Zhou X; Daliani DD
    Clin Genitourin Cancer; 2006 Sep; 5(2):144-9. PubMed ID: 17026803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts.
    Oudard S; Legrier ME; Boyé K; Bras-Gonçalves R; De Pinieux G; De Cremoux P; Poupon MF
    J Urol; 2003 May; 169(5):1729-34. PubMed ID: 12686819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study.
    Font A; Murias A; Arroyo FR; Martin C; Areal J; Sanchez JJ; Santiago JA; Constenla M; Saladie JM; Rosell R
    Ann Oncol; 2005 Mar; 16(3):419-24. PubMed ID: 15668260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
    Nelius T; Klatte T; Yap R; Kalinski T; Röpke A; Filleur S; Allhoff EP
    BJU Int; 2006 Sep; 98(3):580-5. PubMed ID: 16925757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer.
    Hussain M; Smith DC; El-Rayes BF; Du W; Vaishampayan U; Fontana J; Sakr W; Wood D
    Urology; 2003 Apr; 61(4):774-80. PubMed ID: 12670564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer.
    Sinibaldi VJ; Carducci M; Laufer M; Eisenberger M
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):45-8. PubMed ID: 10604269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma.
    Kreis W; Budman DR; Fetten J; Gonzales AL; Barile B; Vinciguerra V
    Ann Oncol; 1999 Jan; 10(1):33-8. PubMed ID: 10076719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer.
    Petrylak DP; Macarthur RB; O'Connor J; Shelton G; Judge T; Balog J; Pfaff C; Bagiella E; Heitjan D; Fine R; Zuech N; Sawczuk I; Benson M; Olsson CA
    J Clin Oncol; 1999 Mar; 17(3):958-67. PubMed ID: 10071290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study.
    Tiffany NM; Ryan CW; Garzotto M; Wersinger EM; Beer TM
    J Urol; 2005 Sep; 174(3):888-92. PubMed ID: 16093981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
    Petrylak DP; Tangen CM; Hussain MH; Lara PN; Jones JA; Taplin ME; Burch PA; Berry D; Moinpour C; Kohli M; Benson MC; Small EJ; Raghavan D; Crawford ED
    N Engl J Med; 2004 Oct; 351(15):1513-20. PubMed ID: 15470214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer.
    Figg WD; Li H; Sissung T; Retter A; Wu S; Gulley JL; Arlen P; Wright JJ; Parnes H; Fedenko K; Latham L; Steinberg SM; Jones E; Chen C; Dahut W
    BJU Int; 2007 May; 99(5):1047-55. PubMed ID: 17437439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer.
    Lin AM; Rini BI; Derynck MK; Weinberg V; Park M; Ryan CJ; Rosenberg JE; Bubley G; Small EJ
    Clin Genitourin Cancer; 2007 Jun; 5(5):323-8. PubMed ID: 17645829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination chemotherapy with docetaxel, vinorelbine and estramustine phosphate in metastatic androgen-resistant prostate cancer: a single institution experience.
    Pectasides D; Pectasides E; Papaxoinis G; Koumarianou A; Psyrri A; Xiros N; Tountas N; Kamposioras K; Papatsibas G; Floros T; Gouveris P; Karageorgopoulou S; Economopoulos T
    Anticancer Res; 2009 Feb; 29(2):769-75. PubMed ID: 19331234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.